



Contents lists available at ScienceDirect

International Journal of Surgery Case Reports

journal homepage: www.casereports.com



Male breast cancer, clinical presentation, diagnosis and treatment: Twenty years of experience in our Breast Unit

A. Sanguinetti^a, A. Polistena^b, R. Lucchini^a, M. Monacelli^c, S. Galasse^a, S. Avenia^d,
R. Triola^a, W. Bugiantella^b, R. Cirocchi^b, F. Rondelli^b, N. Avenia^b

^a S. Maria University Hospital, Terni, Italy

^b University of Perugia, Italy

^c Perugia University Hospital, Italy

^d Medical School University of Perugia, Italy

ARTICLE INFO

Article history:

Available online xxx

Keywords:

Male breast cancer
Genetics
Therapy
Surgery
Radiotherapy
Chemotherapy
Hormonal treatment

ABSTRACT

BACKGROUND: The male breast cancer (MBC) is a rare and represents less than 1% of all malignancies in men and only 1% of all breast cancers incident. We illustrate the experience of our team about the clinico-pathological characteristics, treatment and prognostic factors of patients treated over a period of twenty years.

RESULTS: Forty-seven patients were collected 1995–2014 at the Breast Unit of the Hospital of Terni, Italy. The average age was 67 years and the median time to diagnosis from the onset of symptoms was 16 months. The main clinical complaint was sub areolar swelling in 36, 76% of cases. Most patients have come to our attention with advanced disease. The histology of about ninety percent of the tumors were invasive ductal carcinoma. Management consisted mainly of radical mastectomy; followed by adjuvant radiotherapy and hormonal therapy with or without chemotherapy. The median follow-up was 38 months. The evolution has been characterized by local recurrences; in eight cases (17% of all patients). Metastasis occurred in 15 cases (32% of all patients). The site of bone metastases was in eight cases; lung in four cases; liver in three cases; liver and skin in one case and pleura and skin in one case.

CONCLUSION: The male breast cancer has many similarities to breast cancer in women, but there are distinct functions that need to be appreciated. Future research for a better understanding of the disease should provide a better account of genetic and epigenetic characteristics of these forms; but, above all, epidemiological and biological cohorts numerically more consistent.

© 2016 The Authors. Published by Elsevier Ltd. on behalf of IJS Publishing Group Ltd. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

1. Introduction

Even if rarely, breast cancer (BC) affects men. To date, in Western countries, male breast cancer (MBC) is <1% of all breast tumors and <1% of all cancers in men [1–3]. Its incidence is approximately one case per 100,000 man-years [4]. Recent epidemiological studies suggest that the incidence of MBC is increasing by 1.1% per year [1,2]. MBC incidence is generally low compared with the female BC (FBC), but there is substantial variation between countries. The highest overall rates adjusted for age occur in Israel (1.08 per 100,000 person-years), while the rates are the lowest in South-

east Asia, particularly in Thailand (0.14 per 100,000 person-years) [4]. The reason for this variability is to be found mainly in the genetic susceptibility for the population. Common factors BC risk, such as genetic, hormonal and environmental factors, are involved in the pathogenesis of BC in women as in men. The main predisposing factor MBC is a positive family history (FH) of BC. Patients with a positive first degree FH have a 2.0 times greater risk, which increases to more than 5.0 times with the number of affected relatives and relatives of the first onset, thus suggesting an important role of genetic factors in the risk of MBC [5]. From an epidemiological point of view, the male breast cancer MBC is similar to the female postmenopausal and, in general, treatment MBC follows the same indications postmenopausal FBC. However, the clinical and pathological features of MBC do not exactly match those of the FBC and this would explain why mortality rates and survival are significantly lower in male than in female patients [6]. And now estimated that up to 10% of all the MBCs are hereditary forms caused by germline mutations in inherited well identified susceptibility genes BC. With their mutation frequency and extent of

E-mail addresses: alessandroanguinetti@gmail.com, sanguinettiale@gmail.com (A. Sanguinetti), apolis74@yahoo.it (A. Polistena), robertalucchini@alice.it (R. Lucchini), massimo.monacelli@gmail.com (M. Monacelli), sergio.galasse@gmail.com (S. Galasse), stefano.avenia@libero.it (S. Avenia), atriolaroberta@gmail.com (R. Triola), walterbugiantella@alice.it (W. Bugiantella), roberto.cirocchi@unipg.it (R. Cirocchi), rondellif@hotmail.com (F. Rondelli), nicolaavenia@libero.it (N. Avenia).

<http://dx.doi.org/10.1016/j.ijscr.2016.02.004>

2210-2612/© 2016 The Authors. Published by Elsevier Ltd. on behalf of IJS Publishing Group Ltd. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

their impact in BC susceptibility, these genes can be divided into “high penetrance”, “moderate penetrance” genes and “low penetrance”. Mutations in two genes leading BC high risk, BRCA1 and BRCA2, occur infrequently in the population, but give it a high risk of BC for the individual [11,7]. The moderate risk of BC is determined by genetic variants associated with BRCA1/2 pathways in DNA repair. These variations occur in <1% of the population, and their contribution to the risk of BC is <5% [12,8]. Recently, has been identified third class of low penetrance susceptibility alleles. The low penetrance, however, makes their function of onset of the disease still barely comprehensible. Doubtless, BRCA1 and BRCA2 are the major susceptibility genes in high-risk families. In cases MBC, BRCA2 mutations are much more common than BRCA1. These are responsible for 60–76% of MBC occur in high-risk families, while the frequency of BRCA1 mutations varies from 10% to 16% [13,9,14,10]. The vast majority of BRCA1/2 mutations are truncating mutations; however, it was also identified a large number of missense variants. At present, there is no evidence of a correlation between the position of the mutation in the BRCA1 or BRCA2 gene and the risk of MBC. BRCA1/2 polymorphic variants may also be associated with an increased risk of BC [16,11,18,12]. Interestingly, as there is an association between the variant BRCA2 N372H and the risk of MBC in young men [19,13]. Specific mutations in BRCA1 and BRCA2 show high frequency in specific countries or ethnic groups, in particular, genetically isolated populations; This would explain the higher incidence (>2% in total) in the Ashkenazi Jewish male population than the general population of the United States [20,14,21,15]. Recently were studied specific BRCA-associated phenotypes otherwise identified in MBC [31,16]; it was discovered that most of the MBC BRCA1-related are negative HER2 (HER2), and grade 3 tumors show high proliferative activity. In the study that we propose, we evaluated the clinical pathological characteristics, biological and genetic implications, treatment and prognosis of cases of MBC treated in the Breast Unit of the Hospital “Santa Maria” of Terni in a period of about twenty years.

2. Patients and methods

2.1. Clinical data

It was performed analysis regarding cases of MBC treated in twenty years in a single center. Inclusion criteria were male patients >18 years with localized breast cancer, locally advanced or metastatic. We excluded from the study patients who had no follow-up after initial diagnosis. All the diagnosis of breast cancer had preoperative histological confirmation; tumoral staging was performed with the 2007 edition of the TNM classification. The tumor histological classification was performed using the Scarff-Bloom and Richardson (SBR) system histology. Immuno histochemical analysis to determine the estrogen (ER) and progesterone receptor (PR) status was performed using standard procedures on 4 micron paraffin sections of tissue samples stained with the monoclonal antibodies 6F11 and 1A6 for ER and PR, respectively. 10% nuclear staining was considered a positive result. The description of the clinical data was produced in percentage or in terms of mean and median \pm standard deviation. Survival was calculated using the Kaplan Meier method, and for the evaluation of the relationship between the explanatory variables was used the program[®] XLSTAT—Kovach Computing Services. Anglesey, Wales, UK. The treatment of each patient was determined by the medical staff of the Breast Unit, while the consent, signed by all the patients, was approved by the Multidisciplinary Oncology Group and by the Ethics Committee of the Hospital.

3. Results

3.1. Clinical features

Forty-seven patients at the Breast Unit of the Hospital “Santa Maria” in Terni, Italy, with a diagnosis of breast cancer between January 1995 and December 2014 were retrospectively analyzed and evaluated in terms of general characteristics and survival. The average age was 62 years (range 32–91 years). Family history of breast cancer (HF) was observed in four cases. The main symptom was a solid sub areolar mass in 36 cases, 76%. The tumor was associated with gynecomastia in two cases (4%). Paget's disease was found in one case (2.5%). The median time for the consultation was 28 months (range: 3–48 months). According to the TNM classification, tumors were classified as T1: 4 cases (9%), T2: 9 (18.5%), T4 and T3, 25 and 9 cases, respectively, 52.5% and 20%. In 27 patients (57.2%), locally advanced disease was classified as N1, while in 25.2% of cases (12 patients) was classified as N2. Fourteen patients (30%) is presented with metastatic disease already. He was diagnosed with invasive ductal carcinoma (IDC) in 45 cases (95%); for the two remaining cases this was infiltrating ductal carcinoma with Paget's disease of the breast (2.5%) and infiltrating lobular carcinoma (ILC) (2.5%). According to the classification Scarff-Bloom–Richardson grade II or III was predominant (82% of cases). Axillary lymph nodes containing metastases (N+) in 79.4% of cases (39 patients). In addition, hormonal receptors were evaluated in twenty-three cases. Both estrogen receptor (ER) and progesterone receptor (PR) were positive in 67% (31 patients).

4. Treatment

Thirty-four patients (71%) were treated with radical mastectomy (RM), while the modified radical mastectomy (MRM) was performed in three cases; in the other three cases was performed simple mastectomy (SM), without lymph node dissection, and in only one case was performed lumpectomy. In six patients (13%) was determined only palliative treatment. All patients received adjuvant therapy after surgery. Twenty-three patients of thirty-four patients received radiation therapy; the median dose delivered was 50Gy to the breast, chest wall and regional lymph nodes. Chemotherapy (anthracycline-based protocol, AC60 or FEC 100) was given in the neoadjuvant situation in two cases, in adjuvant situation in nine cases. Delivery chemotherapy increased second special stage and axillary lymph node involvement. Nine cases receive in palliative. Hormone therapy was delivered in twenty patients adjuvant situation: tamoxifen alone in 20 cases, Tamoxifen with orchiectomy in one case. Six patients received palliative. Table 2 summarizes the methods of treatment according to the TNM stage. During the median follow-up of 38 months (3–168 months); evolution has been characterized by local recurrences in eight cases (17% of all patients). Metastasis occurred in 15 cases (32% of all patients). The site of bone metastases was in six cases; lung in four cases; liver in two cases; liver and skin in one case and pleura and skin in one case. The 5 and 10 year overall survival (OS) rates were 63% and 55%.

5. Discussion

Male breast cancer has many similarities to breast cancer in women, but there are distinct functions that need to be appreciated. In recent years, there has been an increase in the incidence of this disease. Review of Surveillance, Epidemiology and End Result data (SEER) indicate an increased incidence of male breast cancer, from 1.0 per 100,000 men in the late 1970s to 1.2 per 100,000 men from 2000 to 2004 [1,2]; this value of incidence has increased steadily,

so that in some countries have already led to 1.4 per 100,000 men. The average age at diagnosis for men with breast cancer is 67 years, which is about 5–10 years the average age at diagnosis for women [1,3]. The average age of our patients (62 years) is slightly lower than that of other series. The male breast cancer is probably caused by the concomitant effects of various risk factors, including clinical disorders related to hormonal imbalances, some occupational exposures and environmental and genetic risk factors, for example, a family history of breast cancer and mutations in the breast cancer predisposing genes, like the BRCA genes, and possibly other [3]. Similar to breast cancer in women, MBC is likely to be caused by the concurrent effects of different risk factors, including clinical disorders relating to hormonal imbalances, certain occupational and environmental exposures, and genetic risk factors, for instance a positive family history (FH) of breast cancer (BC) and mutations in BC predisposing genes, such as BRCA genes, and possibly others. As is the case in female BCs, MBCs are highly sensitive to hormonal changes. In particular, hormonal imbalance between an excess of estrogen and a deficiency of testosterone increases the risk of the disease. This imbalance may occur endogenously due to testicular abnormalities, including, undescended testes, congenital inguinal hernia, orchitis, orchiectomy and testicular injury [10]. Liver diseases, such as cirrhosis, may also result in a hyperestrogenic state [17]. In general, liver damage and disease, caused by the effects of several drugs or their metabolites, may affect hepatic functions and lead to hyperestrogenism. Obesity is one of the most common causes of hyperoestrogenization in men because of increased peripheral aromatization of androgens. Klinefelter's syndrome, characterized by 47XXY karyotype, testicular dysgenesis, gynecomastia, low testosterone concentrations and increased gonadotrophins, is strongly associated with MBC risk. Individuals with this syndrome have a 20–50 times higher risk over the general male population [14]. An upset in estrogen or androgen balance is a causal factor in gynecomastia, which is extremely common in pubescent boys, may occur in men over the age of 50 and is found in 6–38% of male pts affected by BC. However, the incidence of gynecomastia in MBC pts is no higher than in the general male population [6]; gynecomastia, therefore, does not in itself seem to represent a risk factor for MBC [18,15]. As in women, ionizing radiations have been considered as possible causal cofactors in the etiology of MBC [25,19]. Occupational exposure to heat and electromagnetic radiation are postulated to be linked to MBC risk. A higher frequency of breast cancer is reported in men who have worked in hot environments, such as blast furnaces, steel works, rolling and finishing mills [26,20], possibly because long-lasting exposure to high ambient temperatures can lead to testicular failure. As for women, alcoholic beverages seem to represent a risk factor for the development of MBC, with an increase of 16% for each increase of 10 g/day of alcohol intake. Moreover, strong consumers of alcoholic beverages (more than 90 g/day) present a 6-fold increased OR to develop MBC when compared to light consumers (<15 g/day) [28,21]. Overall, with the exception of alcohol consumption, dietary factors seem to play a marginal role in the etiology of MBC. Similar to FBC, a positive FH of BC is associated with increased risk of MBC. Data from population-based studies have shown that about 20% of all MBC pts have a history of BC in a first-degree female relative [17,22,12–16]. In general, a positive FH of either female or male breast cancer among first-degree relatives confers a 2–3-fold increase in MBC risk [18,32,22–33]. The risk increases with increasing numbers of first-degree relatives affected and with early onset in affected relatives. In addition to BC families, MBC cases have also been reported in families with the hereditary non-polyposis colorectal cancer (HNPCC) syndrome [34,24] and Cowden syndrome [35,25]. A personal history of a second primary tumor is reported in more than 11% of MBC pts [36,26]. MBC predisposition can result from germ-line mutations in the high-penetrance BRCA2 (OMIM

#6600185) and, with lower frequency, BRCA1 (OMIM #113705) genes. The presence of MBC within high-risk BC families indicates a high likelihood of BRCA2 mutations with a frequency ranging from 60 to 76%, whereas BRCA1 mutations frequency ranges from 10 to 16% [40,27,41,28]. BRCA2 mutations are currently considered as the major genetic risk factor for MBC, however, there is no evidence for a correlation between the location of the mutation within BRCA2 gene and risk of MBC. The median age at BC diagnosis among BRCA2 mutation carriers is earlier (median, 58.8 years) than that of negative cases (median, 67.9 years) [13]. Male carriers of BRCA2 germ-line mutations have a higher risk of developing BC than men in the general population. Male BRCA2 mutation carriers have been estimated to have a lifetime risk of 6.9% for developing BC, which is approximately 80–100 times higher than in the general population [62,29]. The most common clinical sign of breast cancer onset in men is a painless palpable swelling sub areolar [4]. Other symptoms may include involvement nipple, with retraction and/or ulceration and/or bleeding, axillary lymphadenopathy and gynecomastia [3,4]. Because male breast lobules has not fully formed, the male type of breast cancer is the most common invasive ductal carcinoma (IDC) (85–95%) [4,5]. The result of our study was comparable with a ratio of 95% for IDC and this was significantly higher than the other histological types. Lobular carcinoma in situ, Paget's disease, and inflammatory breast cancer have rarely been described in males [5]. Positivity rate receptor is more common in men with breast cancer, compared to women [30]. In several studies, ER and PR positivity was reported 75–93% [31,32]. In our study, both the estrogen receptor (ER) and progesterone receptor (PR) were positive in 67%. Breast cancer in males should be treated with the same strategy in women [33]. The most common surgical procedure is modified radical mastectomy with axillary node dissection [34]. However, recent studies are in favor of the amendment radical mastectomy or simple combination with radiotherapy. Postoperative radiotherapy does get local control, but no effect was observed on survival [35]. In men treated with mastectomy, adjuvant radiation therapy has been shown to decrease local recurrence [36]. Tamoxifen has been shown to lead to increased survival rates in women with hormone-sensitive disease and today is generally considered the standard adjuvant treatment for male breast cancer hormone-dependent [37]. The tolerance of the drug has not been sufficiently studied in males, and its main side effects are deep vein thrombosis, reduced libido, impotence, mood swings and hot flashes [38]. The chemotherapy should be used in case of absence or doubt on endocrine-reactivity. Frequently used chemotherapy regimens were CMF, FEC and EC [39]. The taxanes may be considered when the lymph nodes are involved. Regarding the use of adjuvant trastuzumab, since there are no specific data, its use should be considered based on the patient and tumor characteristics [40]. The survival rate at 5 and 10 years overall patient with male breast cancer are about 60 and 40%, respectively [41,42]. The number of histologically positive axillary lymph nodes and tumor size were significant prognostic factors. Another negative prognostic factor is the advanced age at the time of diagnosis, as the increased presence of comorbidities may limit the possibility of treatment.

6. Conclusion

The prognosis of the MBC is undoubtedly worse of breast cancer in women. Some researchers justify this by assuming a different and greater biological aggressiveness. We believe, while recognizing that much will be clarified by a better knowledge of their genetic engineering and epigenetic, extremely important collection of studies and pilot retrospective series. Efforts to develop randomized, prospective studies in cooperative groups and other consortia clinical trials are essential.

Conflict of interest

All authors have no conflict of interests.

Funding

All authors have no source of funding.

Ethical approval

Not required.

Authors contributions

Alessandro Sanguinetti, Nicola Avenia: Participated substantially in conception, design, and execution of the study and in the analysis and interpretation of data; also the drafted and editing of the manuscript.

Andrea Polistena, Roberta Lucchini, Massimo Monacelli, Sergio Galasse, Stefano Avenia, Roberta Triola, Walter Bugiantella, Fausto Rondelli, Roberto Cirocchi: Participated substantially in conception, design, and execution of the study and in the analysis and interpretation of data.

References

[1] B. Cutuli, Cohen-Solal Le-Nir C, D. Serin, Y. Kirova, Z. Gaci, C. Lemanski, Male breast cancer, evolution of treatment and prognostic factors. *Analysis of 489 cases*, *Crit. Rev. Oncol. Hematol.* 73 (2010) 246–254.

[2] V. Speirs, A.M. Shaaban, et al., The rising incidence of male breast cancer, *Breast Cancer Res. Treat.* (2008).

[3] A. Yoney, A. Kucuk, M. Unsal, et al., Male breast cancer: a retrospective analysis, *Cancer Radiother.* 13 (2009) 103–107.

[4] L. Fiala, O. Coufal, V. Fait, L. Foretova, et al., Male breast cancer: our experience, *Rozhl. Chir.* 89 (10) (2010) 612–618.

[5] E.A. Ojara, Carcinoma of the male breast in Mulago Hospital, Kampala, *East Afr. Med. J.* 55 (1978) 489–491.

[6] A.J. Sasco, A.B. Lowenfels, P. Pasker-de Jong, Review article: epidemiology of male breast cancer. A meta-analysis of published case control studies and discussion of selected aetiological factors, *Int. J. Cancer* 53 (1993) 538–549.

[7] S.H. Giordano, D.S. Cohen, A.U. Buzdar, et al., Breast carcinoma in men: a population-based study, *Cancer* 101 (2004) 51–57.

[8] S.H. Giordano, A review of the diagnosis and management of male breast cancer, *Oncologist* 10 (2005) 471–479.

[9] D. Palli, G. Masala, R. Mariani-Costantini, et al., A gene-environment interaction between occupation and BRCA1/BRCA2 mutations in male breast cancer? *Eur. J. Cancer* 40 (2004) 2474–2479.

[10] D.B. Thomas, L.M. Jimenez, A. McTiernan, et al., Breast cancer in men: risk factors with hormonal implications, *Am. J. Epidemiol.* 135 (1992) 734–748.

[11] B. D'Avanzo, C. La Vecchia, Risk factors for male breast cancer, *Br. J. Cancer* 71 (1995) 1359–1362.

[12] K.C. Johnson, S. Pan, Y. Mao, Risk factors for male breast cancer in Canada, 1994–1998, *Eur. J. Cancer Prev.* 11 (2002) 253–263.

[13] H.T. Sorensen, M.L. Olsen, L. Mellekjaer, et al., The intrauterine origin of male breast cancer: a birth order study in Denmark, *Eur. J. Cancer Prev.* 14 (2005) 185–186.

[14] R. Hultborn, C. Hanson, I. Kopf, et al., Prevalence of Klinefelter's syndrome in male breast cancer patients, *Anticancer Res.* 17 (1997) 4293–4297.

[15] W. Krause, Male breast cancer—an andrological disease: risk factors and diagnosis, *Andrologia* 36 (2004) 346–354.

[16] D. Palli, M. Falchetti, G. Masala, et al., Association between the BRCA2 N372H variant and male breast cancer risk: a population based case–control study in Tuscany, Central Italy, *BMC Cancer* 7 (2007) 170.

[17] H.T. Sorensen, S. Friis, J.H. Olsen, et al., Risk of breast cancer in men with liver cirrhosis, *Am. J. Gastroenterol.* 93 (1998) 231–233.

[18] M. Ewertz, L. Holmberg, S. Tretli, et al., Risk factors for male breast cancer—a case–control study from Scandinavia, *Acta Oncol.* 40 (2001) 467–471.

[19] D.B. Thomas, K. Rosenblatt, L.M. Jimenez, et al., Ionizing radiation and breast cancer in men (United States), *Cancer Causes Control* 5 (1994) 9–14.

[20] K. Mabuchi, D.S. Bross, I.I. Kessler, Risk factors for male breast cancer, *J. Natl. Cancer Inst.* 74 (1985) 371–375.

[21] P. Guenel, P. Raskmark, J.B. Andersen, E. Lynge, Incidence of cancer in persons with occupational exposure to electromagnetic fields in Denmark, *Br. J. Ind. Med.* 50 (1993) 758–764.

[22] J.T. Casagrande, R. Hanisch, M.C. Pike, et al., A case–control study of male breast cancer, *Cancer Res.* 48 (1988) 1326–1330.

[23] K.A. Rosenblatt, D.B. Thomas, A. McTiernan, et al., Breast cancer in men: aspects of familial aggregation, *J. Natl. Cancer Inst.* 83 (1991) 849–854.

[24] J. Boyd, E. Rhei, M.G. Federici, et al., Male breast cancer in the hereditary nonpolyposis colorectal cancer syndrome, *Breast Cancer Res. Treat.* 53 (1999) 87–91.

[25] J.D. Fackenthal, D.J. Marsh, A.L. Richardson, et al., Male breast cancer in Cowden syndrome patients with germline PTEN mutations, *J. Med. Genet.* 38 (2001) 159–164.

[26] S. Satram-Hoang, A. Ziovas, H. Anton-Culver, Risk of second primary cancer in men with breast cancer, *Breast Cancer Res.* 9 (Suppl. 1) (2007) S10.

[27] D. Thompson, D. Easton, Variation in cancer risks, by mutation position, in BRCA2 mutation carriers, *Am. J. Hum. Genet.* 68 (2001) 410–419.

[28] H. El Omari-Alaoui, I. Lahdiri, I. Nejjar, K. Hadadi, F. Ahyoud, H. Hachi, Male breast cancer, et al: a report of 71 cases, *Cancer Radiother.* 6 (2002) 349–351.

[29] A. Yoney, A. Kucuk, M. Unsal, Male breast cancer: a retrospective analysis, *Cancer Radiother.* 13 (2009) 103–107.

[30] B. Comet, B. Cutuli, F. Penault-Llorca, J. Bonnetterre, Y. Belkacemi, et al., Male breast cancer: a review, *Bull. Cancer* 96 (2) (2009) 181–189.

[31] A. Sanguinetti, A. Polistena, G. D'Ermo, R. Lucchini, R. Triola, C. Conti, S. Avenia, G. Cavallaro, G. De Toma, N. Avenia, Male breast cancer in the twenty-first century: what's new? *Ann. Ital. Chir.* 7 (February (85)) (2014), pii: S0003469 X140 2214 3.

[32] K.B. Contractor, K. Kaur, G.S. Rodrigues, D.M. Kulkarni, H. Singhal, et al., Male breast cancer: is the scenario changing, *World J. Surg. Oncol.* 6 (2008) 58–69.

[33] NCCN (National Comprehensive Cancer Network), *Breast Cancer Guidelines* <http://www.nccn.org>.

[34] Onami Susan, Ozaki Melanie, Mortimer EJoanne, Pal KumarSumanta, et al., Male breast cancer: an update in diagnosis, treatment and molecular profiling, *Maturitas* 65 (2010) 308–314.

[35] E. Yu, H. Suzuki, J. Younus, T. Elfiki, L. Stitt, G. Yau, et al., The Impact of postmastectomy radiation therapy on male breast cancer patients—a case series, *Int. J. Radiat. Oncol. Biol. Phys.* (2011).

[36] K. Pant, U. Dutta, et al., Understanding and management of male breast cancer: a critical review, *Med. Oncol.* 25 (3) (2008) 294–298.

[37] S. Fogh, A.E. Hirsch, J.P. Langmead, S.I. Goldberg, C.L. Rosenberg, A.G. Taghian, S.N. Powell, L.A. Kachnic, et al., Use of tamoxifen with postsurgical irradiation may improve survival in estrogen and progesterone receptor positive male breast cancer, *Clin. Breast Cancer* 11 (1) (2011) 39–45.

[38] N. Arnould, O. Pouget, M. Gharbi, J.-P. Brettes, et al., Breast cancer in men: are there similarities with breast cancer in women? *Gynecol. Obstet. Fertil.* 34 (2006) 413–419.

[39] C. Tunon de Lara, G. Goudy, G. MacGrogan, M. Durand, J.-M. Dilhuydy, A. Avril, et al., Male breast cancer: a review of 52 cases collected at the Institute Bergonie (Bordeaux, France) from 1980 to 2004, *Gynecol. Obstet. Fertil.* 36 (2008) 386–394.

[40] C. Gómez-Raposo, F. Zambrana Tévar, M. Sereno Moyano, M. López Gómez, E. Casado, et al., Male breast cancer, *Cancer Treat. Rev.* 36 (October (6)) (2010) 451–457.

[41] R. Serra, G. Buffone, P. Perri, et al., Male breast cancer manifesting as cephalic vein thrombosis, *Ann. Vasc. Surg.* 27 (8) (2013) e9-1188–e11-1188.

[42] Ottini Laura, Palli Domenico, Rizzo Sergio, Federico Mario, Bazan Viviana, Antonio Russo, et al., Male breast cancer, *Crit. Rev. Oncol. Hematol.* 73 (2010) 141–155.

Open Access

This article is published Open Access at sciedirect.com. It is distributed under the [IJSCR Supplemental terms and conditions](#), which permits unrestricted non commercial use, distribution, and reproduction in any medium, provided the original authors and source are credited.

Please cite this article in press as: A. Sanguinetti, et al., Male breast cancer, clinical presentation, diagnosis and treatment: Twenty years of experience in our Breast Unit, *Int J Surg Case Rep* (2016), <http://dx.doi.org/10.1016/j.ijscr.2016.02.004>